Can Papillary Thyroid Cancer Recur? What to Know as of 2026

Yes, papillary thyroid cancer can recur after treatment ends. Still, because outcomes are favorable for most patients, regular follow-up testing to check for recurrence has become standard management.

Key Summary

• Thyroid cancer's 5-year relative survival rate in Korea is 100.2% (National Cancer Registration Statistics 2019–2023, National Cancer Center Korea), meaning survival is essentially no different from the general population of the same age. However, this is an overall average and is not a figure that ensures any individual's outcome regarding recurrence.
• Recurrence risk is determined by combining tumor size, extrathyroidal extension, the number and size of lymph node metastases, vascular invasion, and whether surgery achieved complete removal, classifying patients into low-, intermediate-, or high-risk groups.
• For patients who underwent total thyroidectomy, blood thyroglobulin levels serve as a key marker for monitoring recurrence. Follow-up is more frequent during the first 1–2 years, then the interval is extended based on risk classification.
• Papillary and follicular carcinomas generally have favorable courses, but medullary and anaplastic carcinomas follow entirely different courses, so they should not be evaluated using the same statistics.

How Is Recurrence Risk Determined?

• Recurrence risk is judged more importantly by risk classification (low, intermediate, high) than by the TNM stage number alone.
• For papillary and follicular carcinomas, age at diagnosis directly factors into staging, so some patients with lymph node metastases at a young age are still classified as lower stage. This means stage alone is often insufficient to properly assess recurrence likelihood.
• Risk classification combines tumor size, whether it extended beyond the thyroid, the number and size of lymph node metastases, vascular invasion, tissue type, and whether surgery achieved complete resection. This classification serves as the basis for deciding the extent of surgery, whether to use radioactive iodine treatment, and the follow-up interval.

In What Order Is Follow-Up Testing Done to Check for Recurrence?

• Step 1: Neck ultrasound is performed at set intervals after surgery.
• Step 2: Blood tests check thyroid hormone, TSH, thyroglobulin, and its antibodies. For patients who underwent total thyroidectomy, thyroglobulin is a key marker for monitoring recurrence.
• Step 3: For medullary carcinoma, calcitonin and CEA are tracked together.
• Step 4: Testing is more frequent during the first 1–2 years, and intervals are extended once results remain stable. Patients with lower risk classification have longer intervals, while those with higher risk have shorter ones.
• Step 5: For metastatic thyroid cancer that no longer responds to radioactive iodine, targeted therapy is considered. If specific genetic alterations such as RET, NTRK, or BRAF are identified, medications matched to those alterations are considered.

FAQ — Does Radioactive Iodine Treatment Reduce Recurrence?

Radioactive iodine treatment is aimed at eliminating remaining thyroid tissue and microscopic metastases, and is considered for patients with high recurrence risk or iodine-avid metastases. It is generally omitted when recurrence risk is low, and is not necessary for every patient. A low-iodine diet and isolation admission may be required before treatment.

FAQ — Do I Need to Keep Getting Follow-Up Testing After Returning Home?

Yes, thyroid cancer is classified as a cancer with a long follow-up period because recurrence can appear late. Neck ultrasound and blood tests (TSH, thyroglobulin, etc.) must be repeated at set intervals, and hormone dose adjustment along with regular ultrasound are relatively easy to continue with local care after returning home. It is advisable to obtain a handover document stating the timing of the next test and the target TSH range, and share it with your local medical team.

Sources and Notes

• This article was written based on notes on thyroid cancer, post-treatment follow-up testing, and targeted therapy (National Cancer Information Center, National Cancer Center Korea, NCCN Guidelines for Patients, National Cancer Registration Statistics 2019–2023, U.S. National Cancer Institute NCI).
• This content is intended to provide general medical information, and actual diagnosis, treatment methods, and outcomes may vary depending on individual condition. Accurate diagnosis and treatment should always be determined through consultation with your medical team.